John Koconis


John has a highly accomplished career as both a strategic and operational leader in the pharmaceutical sector. As CEO, he opened a successful U.S. affiliate for a European based parent company by leveraging his strengths in strategic leadership, portfolio management, business development and innovation commercial execution.


As Global Vice President, Dermatology and Respiratory Disease, he had overall launch responsibility for a major new breakthrough Biologic treatment in the areas of Severe Atopic Dermatitis and Asthma. Other specific career accomplishments include developing patient-centric strategies/cultures, turning around underperforming business models, effectively managing lifecycles of both strategic and non-strategic brands, and developing businesses from preclinical through to commercialization/go-to-market strategy. He also has effectively managed in-licensing/out-licensing activities, led due diligence teams, expanded multiple product portfolios, and acquired a solid understanding of managed care markets in the US and Europe.

Most recently in his position as Global Vice President, Dermatology and Respiratory Diseases at Sanofi -Genzyme, John had overall responsibility for the global Launch of Dupilumab, the first biologic treatment for Moderate to Severe Atopic Dermatitis. John played an active role in the setting of the corporate strategy within the area of Dermatology and Respiratory Diseases (Asthma and Nasal Polyposis). Prior to this, John was the President and CEO of LEO Pharma U.S., a $300 million privately held affiliate of Denmark based, $1.4 billion+, LEO Pharma A/S, John had full P&L responsibility leading efforts to design and build-out a diverse and cross-cultural U.S. organisation from initial stages to a premier Dermatology company in the U.S. In this role he orchestrated the turnaround of the Psoriasis Franchise and established the Actinic Keratosis Franchise in U.S. with the market leading lead brand, Picato®, championed a new patient-centric vision/strategy across all LEO activities, and raised the profit level and revenue by optimising payer and market access strategies.

In his previous positions with LEO, John was the Divisional Director, Critical Care and Dermatology at LEO Pharma/UK where with overall P&L accountability for both of the major commercial Divisions, including directing sales, marketing and medical/KOL liaison functions, he led both divisions to double digit growth, launched new products, and expanded/re-tooled the field force. In prior internationally based roles, John was Director, Corporate Licensing and Business Development, North America at LEO Pharma/Canada, where he successfully launched the North American business development function, including broad responsibilities for strategy development, opportunity identification and assessment, and process development; International Marketing Manager, Critical Care at LEO Pharma A/S – Denmark, where he led global marketing of the Critical Care portfolio in areas of international strategy, coordination of affiliate activities, optimization of product profiles, identification of new opportunities for expansion and overall product profitability.